| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5534554 | HALEON US HOLDINGS | Sucrose ester-C20 to C28 alcohol formulations |
Dec, 2013
(10 years ago) | |
| US4874794 | HALEON US HOLDINGS | Inflammatory disease treatment |
Apr, 2014
(10 years ago) | |
Abreva is owned by Haleon Us Holdings.
Abreva contains Docosanol.
Abreva has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Abreva are:
- US5534554
- US4874794
Abreva was authorised for market use on 25 July, 2000.
Abreva is available in cream;topical dosage forms.
Abreva can be used as treats cold sores/fever blisters on the face or lips. shortens healing time and duration of symptoms: tingling, pain, burning and/or itching.
The generics of Abreva are possible to be released after 28 April, 2014.
Drugs and Companies using DOCOSANOL ingredient
Market Authorisation Date: 25 July, 2000
Treatment: Treats cold sores/fever blisters on the face or lips. shortens healing time and duration of symptoms: tingling, pain, burning and/or itching
Dosage: CREAM;TOPICAL
ABREVA family patents
